Sarepta Therapeutics (NASDAQ:SRPT) has tumbled 12.98% during the past week and has dropped 9.35% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 11.94%. Sarepta Therapeutics (NASDAQ:SRPT) has underperformed the index by 10.17% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Sarepta Therapeutics (NASDAQ:SRPT): The stock opened at $17.74 on Friday but the bulls could not build on the opening and the stock topped out at $17.84 for the day. The stock traded down to $17.10 during the day, due to lack of any buying support eventually closed down at $17.36 with a loss of -0.12% for the day. The stock had closed at $17.38 on the previous day. The total traded volume was 3,470,788 shares.
The company shares have dropped -43.56% from its 1 Year high price. On Oct 5, 2015, the shares registered one year high at $41.97 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $18.32 and the 200 Day Moving Average price is recorded at $21.04.
On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Sarepta Therapeutics, Inc., Behrens M Kathleen had purchased shares worth of $1,165,500 in a transaction dated on March 14, 2016. A total of 75,000 shares were purchased at a price of $15.54 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, Wedbush upgrades its outlook on Sarepta Therapeutics (NASDAQ:SRPT). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Neutral. The brokerage firm raises the price target from $14 per share to $36 per share. The rating by the firm was issued on June 7, 2016. Currently the company Insiders own 10.9% of Sarepta Therapeutics shares according to the proxy statements. Institutional Investors own 76.58% of Sarepta Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 4.44%.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.